The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
Majority of organizations are looking to increase investments in public and hybrid cloud
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Subscribe To Our Newsletter & Stay Updated
